Bishwodip Baral
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Bishwodip Baral has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Ajay M. V. Kumar
International Union Against Tuberculosis and Lung Disease, 2 Rue Jean Lantier, 75001 Paris, France
1 shared publication - Anup Bastola
Sukraraj Tropical & Infectious Disease Hospital, Teku, Kathmandu, Nepal
1 shared publication - Anup Jayaram
Manipal Institute of Virology Manipal Academy of Higher Education, Manipal Udupi Karnataka India
1 shared publication - Avinash K. Sunny
WHO Country Office, Kathmandu 44600, Nepal
1 shared publication - Bimal Sharma Chalise
Sukraraj Tropical and Infectious Disease Hospital, Kathmandu, Nepal
1 shared publication - Hayk Davtyan
Tuberculosis Research and Prevention Center NGO, Yerevan 0014, Armenia
1 shared publication
Latest Publications
- Open Access
- 16 November 2022
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 7 (11) , 381
Audit of Clinical Care Received by COVID-19 Patients Treated at a Tertiary Care Hospital of Nepal in 2021
Like the world over, Nepal was also hard hit by the second wave of COVID-19. We audited the clinical care provided to COVID-19 patients admitted from April to June 2021 in a tertiary care hospital of Nepal. This was a cohort study using routinely collected hospital data. There were 620 patients, and most (458, 74%) had severe illness. The majority (600, 97%) of the patients were eligible for admission as per national guidelines. Laboratory tests helping to predict the outcome of COVID-19, such as D-dimer and C-reactive protein, were missing in about 25% of patients. Nearly all (>95%) patients with severe disease received corticosteroids, anticoagulants and oxygen. The use of remdesivir was low (22%). About 70% of the patients received antibiotics. Hospital exit outcomes of most (>95%) patients with mild and moderate illness were favorable (alive and discharged). Among patients with severe illness, about 25% died and 4% were critically ill, needing further referral. This is the first study from Nepal to audit and document COVID-19 clinical care provision in a tertiary care hospital, thus filling the evidence gap in this area from resource-limited settings. Adherence to admission guidelines was excellent. Laboratory testing, access to essential drugs and data management needs to be improved.
- 16 November 2022
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 7 (11) , 381
Open AccessAudit of Clinical Care Received by COVID-19 Patients Treated at a Tertiary Care Hospital of Nepal in 2021
Like the world over, Nepal was also hard hit by the second wave of COVID-19. We audited the clinical care provided to COVID-19 patients admitted from April to June 2021 in a tertiary care hospital of Nepal. This was a cohort study using routinely collected hospital data. There were 620 patients, and most (458, 74%) had severe illness. The majority (600, 97%) of the patients were eligible for admission as per national guidelines. Laboratory tests helping to predict the outcome of COVID-19, such as D-dimer and C-reactive protein, were missing in about 25% of patients. Nearly all (>95%) patients with severe disease received corticosteroids, anticoagulants and oxygen. The use of remdesivir was low (22%). About 70% of the patients received antibiotics. Hospital exit outcomes of most (>95%) patients with mild and moderate illness were favorable (alive and discharged). Among patients with severe illness, about 25% died and 4% were critically ill, needing further referral. This is the first study from Nepal to audit and document COVID-19 clinical care provision in a tertiary care hospital, thus filling the evidence gap in this area from resource-limited settings. Adherence to admission guidelines was excellent. Laboratory testing, access to essential drugs and data management needs to be improved.